By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN, Feb 4 (Reuters) - Novo Nordisk's shares tumbled as much as 20% ...

The stock tumbled 19% at the opening bell in Copenhagen after its outlook for the year ahead disappointed investors.

COPENHAGEN, Feb 4 () - Novo Nordisk CEO Mike ​Doustdar said on ‌Wednesday that the price reductions ‌for its obesity drug ...

By Harshita Mary Varghese and Patrick Wingrove Jan 28 (Reuters) - Novo Nordisk spent nearly $500 million on U.S. advertising ...

This could finally be the start of the drugmaker's comeback.

Jan 30 (Reuters) - Novo Nordisk's Wegovy pill hit over 26,000 U.S. prescriptions in the second full week after its launch, ...

Novo Nordisk A/S faces a margin crisis as oral Wegovy hits injectable profits. Click for this post-earnings update and see ...

Novo Nordisk, the maker of blockbuster weight-loss drug Wegovy, has warned that profits and sales could fall by as much as 13 ...

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN, Feb 4 (Reuters) - Danish obesity drug giant Novo Nordisk is set ...

Pharmac has taken the first steps towards funding weight loss drug Wegovy after an advisory panel provisionally recommended ...

Novo Nordisk said on Monday its experimental next-generation weight-loss drug CagriSema showed greater reductions in blood ...

Skye Bioscience reports Phase 2a data showing nimacimab plus semaglutide led to over 22% weight loss at 52 weeks, with lower ...